Q2 2021 Results - Reimagining Medicine

Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations BeovuⓇ - Anti-VEGF Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04058067 KINGLET (CRTH258B2304) Diabetic macular edema Phase 3 268 Change in best-corrected visual acuity (BCVA) Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL NCT04278417 (CRTH258D2301) Diabetic retinopathy Phase 3 706 Change from Baseline in BCVA Arm 1: RTH258 (Brolucizumab) 6 mg3 x q6w loading injections, followed by q12w maintenance through week 90 Arm 2: Panretinal photocoagulation laser initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed Chinese patients with visual impairment due to diabetic macular edema Target Patients Read-out Milesstone(s) Publication 2023 Publication planned for 2023 122 Investor Relations | Q2 2021 Results Patients with proliferative diabetic retinopathy 2024 TBD NOVARTIS | Reimagining Medicine

View entire presentation